Jgp Global Gestao De Recursos Ltda. Buys Heavily in Q2 2026

According to filings available via InsiderSet, Jgp Global Gestao De Recursos Ltda. (JGP) demonstrated substantial buying activity in the second quarter of 2026, increasing its portfolio size considerably. The total value of holdings reported as of June 30, 2026, stands at $33,394,146, reflecting a significant increase from previous periods. This investor appears to favor large-cap US stocks and ETFs, with major purchases concentrated in financial institutions, healthcare giants, and technology-related entities.

The most notable purchase during this quarter was XP Inc - Class A (XP), where JGP added over 397,000 shares, representing a massive increase of more than 153% from the prior period. This brings XP's allocation in the portfolio to 23.86%. Another significant addition was ITAU Unibanco Hldng-Pref ADR (ITUB), with JGP acquiring all 167,800 shares held previously, boosting its stake by 100% and increasing the allocation from a prior period to 3.06%.

Additionally, JGP made substantial purchases in several other sectors. VEON Ltd (VEON) saw its stake increase dramatically by over 127% points, adding more than 61,900 shares to reach a 7.78% allocation. Echostar Corp-A (SATS), an entity within the Technology sector, was fully bought in with JGP acquiring all previously held shares, resulting in a full 100% increase and establishing its position at 4.9%. The firm also significantly increased its position in SPDR S&P 500 ETF Trust (SPY) by acquiring all previously held shares, a move that reflects confidence in broad US market performance and brings the allocation to 17.16%.

In terms of sector allocations for this quarter, JGP's portfolio is heavily weighted towards Healthcare (JNJ, UNH, MRK, ABT) and Communication Services (VEON), alongside Technology (SATS). The largest sector allocation is in 'Unknown' holdings at 55.4%, followed by Healthcare at 22.29%. Financial Services (ITUB) accounts for 4.11% and Technology (including SATS) represents a smaller portion of the portfolio.

While JGP primarily focused on buying, there were minor adjustments elsewhere. For instance, ACAD, previously held by the firm, was completely sold out during this period, representing a 100% decrease and exit from the portfolio. Similarly, positions in Revolution Medicines Inc (RVMD) and ABBVie Inc (ABBV) were significantly reduced or exited entirely.

Jgp Global's strategy appears to involve targeted buying into specific large-cap US stocks alongside exposure through popular ETFs like SPY. The overall portfolio value increased substantially, driven by these significant additions. For more detailed information on JGP's holdings and performance, readers can visit InsiderSet.